Technology Pipeline
OsteoFlux™
Is JWP's market-entry product, designed to deliver antibiotics locally within the bone defect site as part of a single-stage surgical approach. By combining natural bone architecture with a proprietary drug-delivery technology, OsteoFlux™ supports infection control while promoting bone regeneration in complex fractures and osteomyelitis. Its localized release strategy is engineered to provide durable antimicrobial activity without compromising the biological integrity of the graft
OsteoSyn™
Is JWP's flagship product, introducing synchronized multi-antibiotic therapy for the treatment of chronic bone infections in complex fractures. Its smart elution profile enables surgeons to eradicate infection in a single operation while accelerating bone regeneration in healing-compromised environments. By enabling limb salvage in high amputation risk cases, OsteoSyn™ promises to be a first-in-class solution—and a potential revolution in the treatment of complex bone infections.
OrthoOncology Expansion Pillar
JWP is expanding its drug-eluting bone graft platform into onco-orthopedic applications, targeting malignancy-driven bone loss directly at the site of disease. By combining localized drug delivery with modulation of the bone microenvironment, this pillar aims to counteract pathological bone loss while supporting structural regeneration, reducing reliance on systemic therapies. This expansion builds on the same core platform technologies as OsteoFlux™ and OsteoSyn™, creating a focused and scalable extension into high-impact clinical areas.
OsteoFlux™
Is JWP's market-entry product, designed to deliver antibiotics locally within the bone defect site as part of a single-stage surgical approach. By combining natural bone architecture with a proprietary drug-delivery technology, OsteoFlux™ supports infection control while promoting bone regeneration in complex fractures and osteomyelitis. Its localized release strategy is engineered to provide durable antimicrobial activity without compromising the biological integrity of the graft